{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:56:35Z","timestamp":1788188195708,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hyperuricemia and dyslipidemia are associated with left ventricular hypertrophy (LVH), while the effect of ApoE gene polymorphism on the correlation between serum uric acid (UA) level and severity of LVH in patients with coronary heart disease (CHD) has not been clarified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective observational study of patients with CHD. Patients were divided into groups of \u03b54 carriers and non-\u03b54 carriers based on sanger sequencing. The association of ApoE \u03b54 gene polymorphism, serum UA level, and LVH, determined by cardiac color Doppler ultrasound, was evaluated by multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 989 CHD patients who underwent ApoE genotyping were enrolled and analyzed. Among them, the frequency of the ApoE \u03b54 genotype was 17.9% (15.7% for E3\/4, 1.1% for E4\/4, and 1.1% for E2\/4). There were 159 patients with LVH, 262 with end-diastolic LV internal diameter (LVEDD) enlargement, 160 with left ventricular ejection fraction (LVEF) reduction, and 154 with heart failure. Multivariate analysis showed that for every increase of 10 \u03bcmol\/L in serum UA level, the risk of LVH decreased in \u03b54 carriers (odds ratio (OR) = 0.94, 95% confidence interval (CI): 0.890\u20130.992, <jats:italic>P<\/jats:italic> = 0.025) and increased in non-\u03b54 carriers (OR = 1.03, 95% CI: 1.005\u20131.049, <jats:italic>P<\/jats:italic> = 0.016). The risk of LVEDD enlargement tended to decrease in \u03b54 carriers (OR = 0.98, 95% CI: 0.943-1.023, <jats:italic>P<\/jats:italic> = 0.391) and increased in non-\u03b54 carriers (OR = 1.03, 95% CI: 1.009\u20131.048, <jats:italic>P<\/jats:italic> = 0.003). The risk of LVEF reduction was reduced in \u03b54 carriers (OR = 0.996, 95% CI: 0.949\u20131.046, <jats:italic>P<\/jats:italic> = 0.872) and increased in non-\u03b54 carriers (OR = 1.02, 95% CI: 0.994\u20131.037, <jats:italic>P<\/jats:italic> = 0.17). The risk of LVEDD enlargement decreased in \u03b54 carriers (OR = 0.98, 95% CI: 0.931\u20131.036, <jats:italic>P<\/jats:italic> = 0.508) and increased in non-\u03b54 carriers (OR = 1.02, 95% CI: 0.998\u20131.042, <jats:italic>P<\/jats:italic> = 0.07).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>High serum UA levels decreased the risk of LVH in ApoE \u03b54 carriers with CHD, while increased the risk of LVH in non-\u03b54 carriers.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1055790","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:20:45Z","timestamp":1671607245000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of ApoE \u03b54 gene polymorphism on the correlation between serum uric acid and left ventricular hypertrophy remodeling in patients with coronary heart disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuibao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc Imag."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","article-title":"Cardiovascular remodelling in coronary artery disease and heart failure","volume":"383","author":"Heusch","year":"2014","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.117.028441","article-title":"Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension. SPRINT (systolic blood pressure intervention trial)","volume":"136","author":"Soliman","year":"2017","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0002-9149(01)01460-6","article-title":"M-mode echocardiographic predictors of 5- to 7-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the cardiovascular health study)","volume":"87","author":"Gardin","year":"2001","journal-title":"Am J Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1253\/circj.CJ-16-0062","article-title":"From left ventricular hypertrophy to dysfunction and failure","volume":"80","author":"Lazzeroni","year":"2016","journal-title":"Circ J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/heartjnl-2011-301528","article-title":"Diagnostic approach and differential diagnosis in patients with hypertrophied left ventricles","volume":"100","author":"Yilmaz","year":"2014","journal-title":"Heart."},{"key":"B7","doi-asserted-by":"publisher","first-page":"495349","DOI":"10.4061\/2011\/495349","article-title":"Left ventricular hypertrophy. Major risk factor in patients with hypertension update and practical clinical applications","volume":"2011","author":"Katholi","year":"2011","journal-title":"Int J Hypertens."},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1536\/Ihj.13-170","article-title":"Serum uric acid is associated with the left ventricular mass index in males of a general population","volume":"55","author":"Yoshimura","year":"2014","journal-title":"Int Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.01.066","article-title":"Usefulness of satisfactory control of low-density lipoprotein cholesterol to predict left ventricular remodeling after a first ST-elevation myocardial infarction successfully re-perfused","volume":"107","author":"Buono","year":"2011","journal-title":"Am J Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/eci.12331","article-title":"Uricaemia and left ventricular mass in hypertensive patients","volume":"44","author":"Catena","year":"2014","journal-title":"Eur J Clin Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5016093","DOI":"10.1155\/2017\/5016093","article-title":"Increased serum uric acid level is a risk factor for left ventricular hypertrophy but not independent of eGFR in patients with type 2 diabetic kidney disease","volume":"2017","author":"Zeng","year":"2017","journal-title":"J Diabetes Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/aje\/155.6.487","article-title":"Apolipoprotein E polymorphism and cardiovascular disease. A HuGE review","volume":"155","author":"Eichner","year":"2002","journal-title":"Am J Epidemiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/archinternmed.2009.234","article-title":"APOE genotype, lipids, and coronary heart disease risk a prospective population study","volume":"169","author":"Ward","year":"2009","journal-title":"Arch Int Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/jnnp.2005.074617","article-title":"Association of APOE e4 and cerebrovascular pathology in traumatic brain injury","volume":"77","author":"Smith","year":"2006","journal-title":"Journal Of Neurology Neurosurgery And Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1096\/fj.201601084R","article-title":"Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden","volume":"31","author":"Trumble","year":"2017","journal-title":"Faseb Journal."},{"key":"B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12944-015-0025-2","article-title":"Association of apolipoprotein E (ApoE) polymorphisms with risk of primary hyperuricemia in Uygur men, Xinjiang, China","volume":"14","author":"Sun","year":"2015","journal-title":"Lipids Health Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110864","article-title":"Apolipoprotein E gene polymorphisms are associated with primary hyperuricemia in a Chinese population","author":"Wu","year":"2014","journal-title":"PLos ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/0471142905.hg0914s38","article-title":"Genotyping of apolipoprotein E. comparative evaluation of different protocols","volume":"9","author":"Ingelsson","year":"2003","journal-title":"Curr Protoc Hum Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"American","year":"2014","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"American college of cardiology\/American heart association task force on practice","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"Guidelines and Committees. ESC\/EAS Guidelines for the management of dyslipidaemias. the Task Force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"Management of arterial hypertension of the European society of and C. European society of. 2007 guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"B23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"18","author":"Atherton","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?","volume":"41","author":"Johnson","year":"2003","journal-title":"Hypertension"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.amjhyper.2006.02.014","article-title":"Serum uric acid is a determinant of metabolic syndrome in a population-based study","volume":"19","author":"Onat","year":"2006","journal-title":"Am J Hypertens."},{"key":"B26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.numecd.2012.01.007","article-title":"Absence of an independent association between serum uric acid and left ventricular mass in Caucasian hypertensive women and men","volume":"23","author":"G Mule","year":"2013","journal-title":"Nutri Metabol Cardiovasc Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.amjhyper.2007.01.013","article-title":"Lack of association between serum uric acid and organ damage in a never treated essential hypertensive population at low prevalence of hyperuricemia","volume":"25","author":"Cuspidi","year":"2007","journal-title":"J Hypertens."},{"key":"B28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nature04001","article-title":"Apolipoprotein-mediated pathways of lipid antigen presentation","volume":"437","author":"Elzen","year":"2005","journal-title":"Nature."},{"key":"B29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2005.09.002","article-title":"Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography","volume":"365","author":"Kand'\u00e1r","year":"2006","journal-title":"Clin Chim Acta"},{"key":"B30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.54.5.351","article-title":"Apolipoprotein E phenotypes in patients with gout. Relation with hypertriglyceridaemia","volume":"54","author":"Moriwaki","year":"1995","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0891-5849(93)90143-I","article-title":"Towards the physiological function of uric acid","volume":"14","author":"Becker","year":"1993","journal-title":"Free Radic Biol Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1101\/sqb.2002.67.483","article-title":"Extracellular superoxide dismutase, uric acid, and atherosclerosis","volume":"67","author":"Hink","year":"2002","journal-title":"Cold Spring Harb Symp Quant Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1161\/01.ATV.0000027524.86752.02","article-title":"Peroxidase properties of extracellular superoxide dismutase. Role of uric acid in modulating in vivo activity","volume":"22","author":"HHink","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/CS20030149","article-title":"Uric acid reduces exercise-induced oxidative stress in healthy adults","volume":"105","author":"Waring","year":"2003","journal-title":"Clin Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.2337\/db06-0283","article-title":"Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers","volume":"55","author":"Waring","year":"2006","journal-title":"Diabetes."},{"key":"B36","first-page":"E107","article-title":"Reduction of serum uric acid associated with attenuation of renal injury, inflammation and macrophages M1\/M2 ratio in hyperuricemic mice model","volume":"64","author":"Haryono","year":"2018","journal-title":"Kobe J Med Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/mi.2015.65","article-title":"CD11c(+) monocyte\/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23","volume":"9","author":"Arnold","year":"2016","journal-title":"Mucosal Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.imlet.2016.06.001","article-title":"Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose","volume":"176","author":"Torres-Castro","year":"2016","journal-title":"Immunol Lett."},{"key":"B39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41467-017-00231-1","article-title":"CD206(+) M2-like macrophages regulate systemic glucose metabolism by inhibiting proliferation of adipocyte progenitors","volume":"8","author":"Nawaz","year":"2017","journal-title":"Nat Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J Exp Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4110\/in.2019.19.e21","article-title":"Prominent inflammatory features of monocytes\/macrophages in acute calcium pyrophosphate crystal arthritis. A comparison with acute gouty arthritis","volume":"19","author":"Jeong","year":"2019","journal-title":"Immune Netw."},{"key":"B42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2015.11.015","article-title":"Saturated fatty acids trigger TLR4-mediated inflammatory response","volume":"244","author":"Rocha","year":"2016","journal-title":"Atherosclerosis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1038\/emm.2013.97","article-title":"Recognition of lipopolysaccharide pattern by TLR4 complexes","volume":"45","author":"Park","year":"2013","journal-title":"Exp Mol Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/01.LAB.0000097190.56734.FE","article-title":"Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells","volume":"83","author":"Harada","year":"2003","journal-title":"Lab Invest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jsps.2016.07.002","article-title":"An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice","volume":"25","author":"Salahudeen","year":"2017","journal-title":"Saudi Pharm J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3892\/mmr.2019.10426","article-title":"Urate transport capacity of glucose transporter 9 and urate transporter 1 in cartilage chondrocytes","volume":"20","author":"Zhang","year":"2019","journal-title":"Mol Med Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jbspin.2004.06.007","article-title":"Response to a urate-lowering diet according to polymorphisms in the apolipoprotein AI-CIII-AIV cluster","volume":"32","author":"Cardona","year":"2005","journal-title":"J Rheumatol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1055790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:20:48Z","timestamp":1671607248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1055790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":47,"alternative-id":["10.3389\/fcvm.2022.1055790"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1055790","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"article-number":"1055790"}}